Edwards Preparing Prima Plus Stentless Heart Valve Postmarket Study
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences is preparing for a postmarket study to evaluate long-term effectiveness of the XenoLogiX anticalcification treatment used with its Prima Plus stentless porcine tissue heart valve following FDA approval of the valve Feb. 27.
You may also be interested in...
Medtronic launching Freestyle stentless porcine heart valve at a premium to St. Jude's Toronto SPV.
MEDTRONIC PRICING FREESTYLE VALVE AT PREMIUM TO ST. JUDE's TORONTO SPV, indicating a belief that the "advanced tissue technology" gives Medtronic an edge over its only competitor in the U.S. stentless porcine heart valve market. Premarket approval applications for the Medtronic and St. Jude stentless porcine heart valves cleared FDA on Nov. 25 and Nov. 24, respectively.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.